01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

#HVO hVIVO PLC – £2.5m contract for Omicron characterisation study June 3, 2024 – Posted in: hVIVO (HVO)

• Characterisation study to establish world’s first Omicron BA.5 challenge model • Study to utilise hVIVO’s new state-of-the-art containment level 3 (CL3) quarantine facilities in Canary Wharf • FluCamp to recruit healthy 18-30 year old seropositive volunteers who have previously completed a course of COVID-19 vaccination • New quarantine unit in Canary Wharf facilitates the expansion of hVIVO’s world leading portfolio of human challenge models   hVIVO plc (AIM & Euronext: HVO), a fast growing…

Continue reading

#VELA investee co. #KING Igraine PLC – Interim Results for the Half-Year to 30 June 2023 September 29, 2023 – Posted in: Blog, Vela Technologies Plc (VELA)

Interim Results for the Half-Year to 30 June 2023 Igraine plc, Directors Statement We are pleased to present the interim results for Igraine plc (AQUIS: KING) for the period ending 30 June 2023. This reporting period has unfolded in a challenging economic environment, but we are encouraged by the positive developments in our ongoing discussions and commercialisation efforts. Despite the economic headwinds, our maiden investment with Excalibur Medicines Ltd (“EML”) continues to progress positively. Igraine…

Continue reading

#HVO hVIVO PLC – Presentation at World Vaccine Congress March 29, 2023 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that Dr Andrew Catchpole, Chief Scientific Officer, will be delivering a presentation at the World Vaccine Congress, Washington D.C., United States. Full details of the presentation are included below:   Title Challenge Studies – can the results be expected to mimic…

Continue reading

#HVO hVIVO plc – Omicron human challenge model update March 16, 2023 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that its Omicron human challenge agent has been successfully manufactured.     Subject to the successful completion of the characterisation study and receipt of relevant regulatory approvals, this has expanded the Company’s unique portfolio to 11 human challenge models to test a…

Continue reading

#HVO hVIVO PLC – £6.8m RSV human challenge contract signed February 6, 2023 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has signed a £6.8m contract with a leading pharmaceutical company based in Asia Pacific (“APAC”), to test its respiratory syncytial virus (“RSV”) antiviral drug candidate, using the hVIVO RSV Human Challenge Study Model.                                 The Phase 2a double-blinded placebo-controlled…

Continue reading

#ORPH Open Orphan – Inside the quarantine lab where Irish company infects humans with Covid October 18, 2021 – Posted in: Blog, Open Orphan (ORPH)

  Step into the foyer of the Whitechapel Hotel in London and it seems no different from any other business. But venture further in, and it becomes clear that something very strange is going on in this former textile factory. Biohazard signs on each floor warn observers not to enter. Next to the double beds in the bright and modern en-suite rooms are white trolleys containing swabs, vials, gloves and other medical paraphernalia. Peepholes on…

Continue reading